Promega expands life science products with takeover of Turner
BioSystems
9 August 2009
Promega Corporation announces the recent purchase of Turner
BioSystems Inc. to grow their mutual interest in offering high quality
integrated systems (optimized instrument with reagents) to life
scientists in research, drug discovery and clinical diagnostics.
The company says that the expansion continues in which they have
delivered integrated bioluminescent systems with Turner’s luminometers
and world-class bioluminescent technologies from Promega.
“This is a natural next move for Turner,” explains Turner President
Mike Molkelke. “Over the years, innovating with Promega has created
productive instrument/reagent systems that scientists highly value. Both
companies are eager to optimize this total systems approach for the
bench top.”
“The Turner quality and our long standing relationship make this a
great enhancement for all of our customers,” says Promega CEO Bill
Linton. “Scientists value quality integrated systems because it frees
them up to focus on the other demands in their lab. This purchase allows
us to offer these systems for more applications.”
Turner and Promega have worked together in offering the Glomax
Luminometer line that is optimized for Promega bioluminescent assays.
Turner offers microplate and single tube reader luminometers,
fluorometers, photometers and multimode instruments for life science
labs. Turner will continue its operations out of Sunnyvale, CA.
Promega's 2,000 products enable scientists worldwide to advance their
knowledge in genomics, proteomics, cellular analysis, molecular
diagnostics and human identification. Founded in 1978, the company is
headquartered in Madison, WI, USA with branches in 14 countries and has
over 50 global distributors.
Bookmark this page